Review of cancer therapies for the perioperative physician

Table 3 Classification of small molecule target therapy (‐ibs), intracellular target, and side effects

Small molecule	End with name	Target	Target action	Side effect
Tyrosine kinase inhibitors	‐tinib over 50 FDA approved	EGFR, VEGFR, PDGFR, FGFR, SCGFR, ALK, ERBB2, ITK, LCK, BTK, CDK	Inhibit cell function, growth factors, proliferation, angiogenesis	High blood pressure, bleeding, thrombosis, periorbital edema, cardiomyopathy
Proteasome inhibitors	‐zomib Bortezomib (Velada) Carfilzomib (Kyprolis) Ixazomib (Ninlaro)	Proteasome	Apoptosis‐cell death	Pancytopenia, peripheral neuropathy, diarrhea
Cyclin‐dependent inhibitors (CDK)	‐ciclib Abemaciclib (Verzenio) Palbociclib (Ibrance) Ribociclib (Kisqali)	CDK4/6‐HER2	DNA synthesis‐cell death	Bone marrow suppression
Poly‐ADP‐ribosome polymerase inhibitors (PARP)	‐parib Olaparib (Lynparza) Niraparib (Zejula) Rucaparib (Rubraca) Talazoparib (Talzenna)	PARP‐BRACA1, BRACA2	Inhibits DNA repair‐cell death	Bone marrow suppression, MDS, AML, HTN, hypertensive crisis

EGFR Epidermal growth factor receptor, VEGFR Vasoendothelial growth factor receptor, PDGFR Platelet‐derived growth factor receptor, FGFR Fibroblast growth factor, SCGFR Stem cell growth factor, ALK Anaplastic lymphoma kinase, ERBB2 Breast cancer, ITK Interleukin‐2 receptor, LCK Leukocyte-specific protein kinase, BTK Bruton‐B-cell‐specific kinase, CDK Cyclic-dependent kinase, HER2 Breast cancer receptor, BRACA1, BRACA2 Breast cancer gene, MDS Myelodysplastic syndrome, AML Acute myeloid leukemia, HTN Hypertension

ISSN: 2047-0525